▶ 調査レポート

世界の抗腫瘍薬市場（2023～2030）：疾患別（乳がん、白血病、肺がん）、投与経路別（筋肉内、腹腔内、静脈内）、薬剤クラス別、流通チャネル別、エンドユーザー別
• 英文タイトル：Anti-Tumor Drugs Market by Indications (Breast Cancer, Leukemia, Lung Cancer), Route of Administration (Intra-muscular, Intraperitoneal, Intravenous), Drug Class, Distribution Channels, End User - Global Forecast 2023-2030

360iResearchが調査・発行した産業分析レポートです。世界の抗腫瘍薬市場（2023～2030）：疾患別（乳がん、白血病、肺がん）、投与経路別（筋肉内、腹腔内、静脈内）、薬剤クラス別、流通チャネル別、エンドユーザー別 / Anti-Tumor Drugs Market by Indications (Breast Cancer, Leukemia, Lung Cancer), Route of Administration (Intra-muscular, Intraperitoneal, Intravenous), Drug Class, Distribution Channels, End User - Global Forecast 2023-2030 / MRC2311A0174資料のイメージです。• レポートコード：MRC2311A0174
• 出版社/出版日：360iResearch / 2023年10月25日
• レポート形態：英文、PDF、186ページ
• 納品方法：Eメール（受注後2-3日）
• 産業分類：医薬品
• 販売価格（消費税別）
  Single User（1名利用、印刷不可、1年間閲覧）￥592,350 (USD3,949)▷ お問い合わせ
  Site License（同一拠点内共有可、印刷可）￥1,042,350 (USD6,949)▷ お問い合わせ
• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
抗腫瘍薬市場規模は、2022年の311億3,000万米ドルから2030年には783億5,000万米ドルに達すると予測、予測期間中の年平均成長率は12.22%になる見込みです。
市場細分化とカバー範囲：
この調査レポートは、抗腫瘍薬市場の包括的な見通しを提供するために、様々なサブ市場を分析し、収益を予測し、各カテゴリの新たな動向を調査しています。
● 適応症別では、乳がん、白血病、肺がん、黒色腫、前立腺がんについて調査しています。前立腺がんは予測期間中に大きな市場シェアを獲得すると予測されています。
● 投与経路別では、筋肉内、腹腔内、静脈内、髄腔内、膀胱内、経口、皮下、局所が調査対象です。外用薬は予測期間中に大きな市場シェアを占めると予測されています。
● 薬剤クラス別では、細胞毒性療法、ホルモン療法、標的療法が調査対象です。標的療法はさらに、モノクローナル抗体と低分子阻害剤で調査しています。ホルモン療法は予測期間中に大きな市場シェアを占めると予測されています。
● 流通チャネル別では、病院薬局と小売薬局の市場を調査しています。病院薬局は予測期間中に大きな市場シェアを獲得すると予測されます。
● エンドユーザー別では、診療所、病院、専門センターの市場を調査しています。病院は予測期間中に大きな市場シェアを獲得すると予測されます。
● 地域別では、南北アメリカ、アジア太平洋、ヨーロッパ、中東、アフリカで調査を行いました。詳しい内訳は、南北アメリカはアルゼンチン、ブラジル、カナダ、メキシコ、アメリカを対象に、アメリカはさらにカリフォルニア、フロリダ、イリノイ、ニューヨーク、オハイオ、ペンシルバニア、テキサスを対象に調査を行いました。アジア太平洋地域は、オーストラリア、中国、インド、インドネシア、日本、マレーシア、フィリピン、シンガポール、韓国、台湾、タイ、ベトナムでした。ヨーロッパ・中東・アフリカは、デンマーク、エジプト、フィンランド、フランス、ドイツ、イスラエル、イタリア、オランダ、ナイジェリア、ノルウェー、ポーランド、カタール、ロシア、サウジアラビア、南アフリカ、スペイン、スウェーデン、スイス、トルコ、アラブ首長国連邦、イギリスを対象としています。2022年の市場シェアは南北アメリカが38.75%で最大、次いでヨーロッパ、中東・アフリカでした。

市場統計：
本レポートでは、主要7通貨（米ドル、ユーロ、日本円、英ポンド、豪ドル、カナダドル、スイスフラン）の市場規模と予測を提供しています。本レポートでは、2018年から2021年を過去年、2022年を基準年、2023年を推定年、2024年から2030年を予測期間としています。

FPNVポジショニングマトリックス：
FPNVポジショニングマトリックスは、抗腫瘍薬市場を評価するための不可欠なツールです。事業戦略と製品満足度に関連する主要指標を分析し、ベンダーを包括的に評価します。これにより、ユーザーは特定のニーズに合わせた情報に基づいた意思決定を行うことができます。高度な分析により、ベンダーは4つの象限に分類され、それぞれ成功のレベルが異なります： フォアフロント（F）、パスファインダー（P）、ニッチ（N）、バイタル（V）です。この洞察に満ちたフレームワークにより、意思決定者は自信を持って市場をナビゲートすることができます。

市場シェア分析：
市場シェア分析では、抗腫瘍薬市場のベンダーランドスケープに関する貴重な洞察を提供します。全体的な収益、顧客基盤、その他の主要指標に対する影響を評価することで、各社の業績と直面している競争環境について包括的な理解を提供します。この分析では、調査期間中の市場シェア獲得、断片化、優位性、業界再編などの競争レベルも明らかにします。

主要企業のプロフィール：
本レポートでは、抗腫瘍薬市場における最近の重要な動向を掘り下げ、主要ベンダーとその革新的なプロフィールを紹介しています。これには、AbbVie Inc., Amgen inc., Astellas Pharma Inc., AstraZeneca PLC, Bayer AG, Biogen Inc., Bristol-Myers Squibb Company, Celgene Corporation, Cybrexa Therapeutics, Dr. Reddy’s Laboratories Ltd., Eisai Co., Ltd., Eli Lilly and Company, F. Hoffmann-La Roche Ltd, Genentech, Inc., Getwell Oncology, GLS Pharma Pvt. Ltd., Merck & Co., Inc., Novartis AG, Otsuka Pharmaceutical Co., Ltd, Pfizer Inc., PharmaMar, Sanofi SA, Taiho Oncology, Inc, Takeda Pharmaceutical Company Limited, and Teva Pharmaceutical Industries Ltdなどが含まれます。

本レポートでは、以下の点について貴重な洞察を提供しています：
1. 市場浸透： 主要企業の市場ダイナミクスと製品に関する包括的な情報を提供します。
2. 市場開拓： 新興市場と成熟市場セグメントへの浸透を詳細に分析し、有利な機会を強調します。
3. 市場の多様化： 新製品の発売、未開拓の地域、最近の開発、投資に関する詳細情報を記載しています。
4. 競合他社の評価とインテリジェンス： 主要企業の市場シェア、戦略、製品、認証、規制当局の承認、特許状況、製造能力を網羅的に評価しています。
5. 製品開発とイノベーション： 将来の技術、研究開発活動、画期的な製品開発に関する知的洞察を行いました。

本レポートは、以下のような主要な質問に対応しています：
1. 抗腫瘍薬市場の市場規模および予測はどのようになっていますか？
2. 抗腫瘍薬市場で最も高い投資ポテンシャルを持つ製品、セグメント、用途、分野はどこですか？
3. 抗腫瘍薬市場の機会を特定するための競争戦略窓口はどのようになっていますか？
4. 抗腫瘍薬市場における最新の技術動向と規制の枠組みはどのようになっていますか？
5. 抗腫瘍薬市場における主要ベンダーの市場シェアはどのようになっていますか？
6. 抗腫瘍薬市場への参入に適したモードと戦略的動きはどのようになっていますか？

1. 序論
2. 調査方法
3. エグゼクティブサマリー
4. 市場概要
5. 市場インサイト
6. 抗腫瘍薬の市場分析：疾患別
7. 抗腫瘍薬の市場分析：投与経路別
8. 抗腫瘍薬の市場分析：薬剤クラス別
9. 抗腫瘍薬の市場分析：流通チャネル別
10. 抗腫瘍薬の市場分析：エンドユーザー別
11. 南北アメリカの抗腫瘍薬市場
12. アジア太平洋の抗腫瘍薬市場
13. ヨーロッパ・中東・アフリカの抗腫瘍薬市場
14. 競争状況
15. 競争ポートフォリオ
16. 付録

レポート目次

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Anti-Tumor Drugs Market, by Region
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Rise in incidence of cancer with the surge in the geriatric population
5.1.1.2. Growing awareness regarding early diagnosis and treatment for the cancer
5.1.1.3. Increase in expenditures on healthcare by government
5.1.2. Restraints
5.1.2.1. High cost of anticancer drugs and low survival rate
5.1.3. Opportunities
5.1.3.1. Availability of pipelined drugs and upsurge in demand for personalized medicines for the tumor treatment
5.1.3.2. Recent innovations in anticancer therapies
5.1.4. Challenges
5.1.4.1. Unfavorable outcomes associated with the use of cancer drugs
5.2. Market Segmentation Analysis
5.3. Market Trend Analysis
5.4. Cumulative Impact of COVID-19
5.5. Cumulative Impact of Russia-Ukraine Conflict
5.6. Cumulative Impact of High Inflation
5.7. Porter’s Five Forces Analysis
5.7.1. Threat of New Entrants
5.7.2. Threat of Substitutes
5.7.3. Bargaining Power of Customers
5.7.4. Bargaining Power of Suppliers
5.7.5. Industry Rivalry
5.8. Value Chain & Critical Path Analysis
5.9. Regulatory Framework
5.10. Client Customization
6. Anti-Tumor Drugs Market, by Indications
6.1. Introduction
6.2. Breast Cancer
6.3. Leukemia
6.4. Lung Cancer
6.5. Melanoma
6.6. Prostate Cancer
7. Anti-Tumor Drugs Market, by Route of Administration
7.1. Introduction
7.2. Intra-muscular
7.3. Intraperitoneal
7.4. Intravenous
7.5. Intraventricular or Intrathecal
7.6. Intravesicular
7.7. Oral
7.8. Subcutaneous
7.9. Topical
8. Anti-Tumor Drugs Market, by Drug Class
8.1. Introduction
8.2. Cytotoxics
8.3. Hormonal Therapy
8.4. Targeted Therapy
8.5.1. Monoclonal Antibodies
8.5.2. Small Molecule Inhibitors
9. Anti-Tumor Drugs Market, by Distribution Channels
9.1. Introduction
9.2. Hospital Pharmacies
9.3. Retail Pharmacies
10. Anti-Tumor Drugs Market, by End User
10.1. Introduction
10.2. Clinics
10.3. Hospitals
10.4. Specialty Centers
11. Americas Anti-Tumor Drugs Market
11.1. Introduction
11.2. Argentina
11.3. Brazil
11.4. Canada
11.5. Mexico
11.6. United States
12. Asia-Pacific Anti-Tumor Drugs Market
12.1. Introduction
12.2. Australia
12.3. China
12.4. India
12.5. Indonesia
12.6. Japan
12.7. Malaysia
12.8. Philippines
12.9. Singapore
12.10. South Korea
12.11. Taiwan
12.12. Thailand
12.13. Vietnam
13. Europe, Middle East & Africa Anti-Tumor Drugs Market
13.1. Introduction
13.2. Denmark
13.3. Egypt
13.4. Finland
13.5. France
13.6. Germany
13.7. Israel
13.8. Italy
13.9. Netherlands
13.10. Nigeria
13.11. Norway
13.12. Poland
13.13. Qatar
13.14. Russia
13.15. Saudi Arabia
13.16. South Africa
13.17. Spain
13.18. Sweden
13.19. Switzerland
13.20. Turkey
13.21. United Arab Emirates
13.22. United Kingdom
14. Competitive Landscape
14.1. FPNV Positioning Matrix
14.2. Market Share Analysis, By Key Player
14.3. Competitive Scenario Analysis, By Key Player
15. Competitive Portfolio
15.1. Key Company Profiles
15.1.1. AbbVie Inc.
15.1.2. Amgen inc.
15.1.3. Astellas Pharma Inc.
15.1.4. AstraZeneca PLC
15.1.5. Bayer AG
15.1.6. Biogen Inc.
15.1.7. Bristol-Myers Squibb Company
15.1.8. Celgene Corporation
15.1.9. Cybrexa Therapeutics
15.1.10. Dr. Reddy’s Laboratories Ltd.
15.1.11. Eisai Co., Ltd.
15.1.12. Eli Lilly and Company
15.1.13. F. Hoffmann-La Roche Ltd
15.1.14. Genentech, Inc.
15.1.15. Getwell Oncology
15.1.16. GLS Pharma Pvt. Ltd.
15.1.17. Merck & Co., Inc.
15.1.18. Novartis AG
15.1.19. Otsuka Pharmaceutical Co., Ltd
15.1.20. Pfizer Inc.
15.1.21. PharmaMar
15.1.22. Sanofi SA
15.1.23. Taiho Oncology, Inc
15.1.24. Takeda Pharmaceutical Company Limited
15.1.25. Teva Pharmaceutical Industries Ltd.
15.2. Key Product Portfolio
16. Appendix
16.1. Discussion Guide
16.2. License & Pricing

TABLE 1. ANTI-TUMOR DRUGS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018–2022
TABLE 3. ANTI-TUMOR DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL ANTI-TUMOR DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
TABLE 6. ANTI-TUMOR DRUGS MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 7. ANTI-TUMOR DRUGS MARKET SIZE, BY LEUKEMIA, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. ANTI-TUMOR DRUGS MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. ANTI-TUMOR DRUGS MARKET SIZE, BY MELANOMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. ANTI-TUMOR DRUGS MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 12. ANTI-TUMOR DRUGS MARKET SIZE, BY INTRA-MUSCULAR, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. ANTI-TUMOR DRUGS MARKET SIZE, BY INTRAPERITONEAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. ANTI-TUMOR DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. ANTI-TUMOR DRUGS MARKET SIZE, BY INTRAVENTRICULAR OR INTRATHECAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. ANTI-TUMOR DRUGS MARKET SIZE, BY INTRAVESICULAR, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. ANTI-TUMOR DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. ANTI-TUMOR DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. ANTI-TUMOR DRUGS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 21. ANTI-TUMOR DRUGS MARKET SIZE, BY CYTOTOXICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. ANTI-TUMOR DRUGS MARKET SIZE, BY HORMONAL THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. ANTI-TUMOR DRUGS MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. ANTI-TUMOR DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 25. ANTI-TUMOR DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. ANTI-TUMOR DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 28. ANTI-TUMOR DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. ANTI-TUMOR DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 31. ANTI-TUMOR DRUGS MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. ANTI-TUMOR DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. ANTI-TUMOR DRUGS MARKET SIZE, BY SPECIALTY CENTERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. AMERICAS ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
TABLE 35. AMERICAS ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 36. AMERICAS ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 37. AMERICAS ANTI-TUMOR DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 38. AMERICAS ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 39. AMERICAS ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 40. AMERICAS ANTI-TUMOR DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 41. ARGENTINA ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
TABLE 42. ARGENTINA ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 43. ARGENTINA ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 44. ARGENTINA ANTI-TUMOR DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 45. ARGENTINA ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 46. ARGENTINA ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 47. BRAZIL ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
TABLE 48. BRAZIL ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 49. BRAZIL ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 50. BRAZIL ANTI-TUMOR DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 51. BRAZIL ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 52. BRAZIL ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 53. CANADA ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
TABLE 54. CANADA ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 55. CANADA ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 56. CANADA ANTI-TUMOR DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 57. CANADA ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 58. CANADA ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 59. MEXICO ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
TABLE 60. MEXICO ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 61. MEXICO ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 62. MEXICO ANTI-TUMOR DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 63. MEXICO ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 64. MEXICO ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 65. UNITED STATES ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
TABLE 66. UNITED STATES ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 67. UNITED STATES ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 68. UNITED STATES ANTI-TUMOR DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 69. UNITED STATES ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 70. UNITED STATES ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 71. UNITED STATES ANTI-TUMOR DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 72. ASIA-PACIFIC ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
TABLE 73. ASIA-PACIFIC ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 74. ASIA-PACIFIC ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 75. ASIA-PACIFIC ANTI-TUMOR DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 76. ASIA-PACIFIC ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 77. ASIA-PACIFIC ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 78. ASIA-PACIFIC ANTI-TUMOR DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 79. AUSTRALIA ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
TABLE 80. AUSTRALIA ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 81. AUSTRALIA ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 82. AUSTRALIA ANTI-TUMOR DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 83. AUSTRALIA ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 84. AUSTRALIA ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 85. CHINA ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
TABLE 86. CHINA ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 87. CHINA ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 88. CHINA ANTI-TUMOR DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 89. CHINA ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 90. CHINA ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 91. INDIA ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
TABLE 92. INDIA ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 93. INDIA ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 94. INDIA ANTI-TUMOR DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 95. INDIA ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 96. INDIA ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 97. INDONESIA ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
TABLE 98. INDONESIA ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 99. INDONESIA ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 100. INDONESIA ANTI-TUMOR DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 101. INDONESIA ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 102. INDONESIA ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 103. JAPAN ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
TABLE 104. JAPAN ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 105. JAPAN ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 106. JAPAN ANTI-TUMOR DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 107. JAPAN ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 108. JAPAN ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 109. MALAYSIA ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
TABLE 110. MALAYSIA ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 111. MALAYSIA ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 112. MALAYSIA ANTI-TUMOR DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 113. MALAYSIA ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 114. MALAYSIA ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 115. PHILIPPINES ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
TABLE 116. PHILIPPINES ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 117. PHILIPPINES ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 118. PHILIPPINES ANTI-TUMOR DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 119. PHILIPPINES ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 120. PHILIPPINES ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 121. SINGAPORE ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
TABLE 122. SINGAPORE ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 123. SINGAPORE ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 124. SINGAPORE ANTI-TUMOR DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 125. SINGAPORE ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 126. SINGAPORE ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 127. SOUTH KOREA ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
TABLE 128. SOUTH KOREA ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 129. SOUTH KOREA ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 130. SOUTH KOREA ANTI-TUMOR DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 131. SOUTH KOREA ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 132. SOUTH KOREA ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 133. TAIWAN ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
TABLE 134. TAIWAN ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 135. TAIWAN ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 136. TAIWAN ANTI-TUMOR DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 137. TAIWAN ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 138. TAIWAN ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 139. THAILAND ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
TABLE 140. THAILAND ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 141. THAILAND ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 142. THAILAND ANTI-TUMOR DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 143. THAILAND ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 144. THAILAND ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 145. VIETNAM ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
TABLE 146. VIETNAM ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 147. VIETNAM ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 148. VIETNAM ANTI-TUMOR DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 149. VIETNAM ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 150. VIETNAM ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 151. EUROPE, MIDDLE EAST & AFRICA ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
TABLE 152. EUROPE, MIDDLE EAST & AFRICA ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 153. EUROPE, MIDDLE EAST & AFRICA ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 154. EUROPE, MIDDLE EAST & AFRICA ANTI-TUMOR DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 155. EUROPE, MIDDLE EAST & AFRICA ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 156. EUROPE, MIDDLE EAST & AFRICA ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 157. EUROPE, MIDDLE EAST & AFRICA ANTI-TUMOR DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 158. DENMARK ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
TABLE 159. DENMARK ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 160. DENMARK ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 161. DENMARK ANTI-TUMOR DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 162. DENMARK ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 163. DENMARK ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 164. EGYPT ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
TABLE 165. EGYPT ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 166. EGYPT ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 167. EGYPT ANTI-TUMOR DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 168. EGYPT ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 169. EGYPT ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 170. FINLAND ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
TABLE 171. FINLAND ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 172. FINLAND ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 173. FINLAND ANTI-TUMOR DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 174. FINLAND ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 175. FINLAND ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 176. FRANCE ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
TABLE 177. FRANCE ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 178. FRANCE ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 179. FRANCE ANTI-TUMOR DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 180. FRANCE ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 181. FRANCE ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 182. GERMANY ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
TABLE 183. GERMANY ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 184. GERMANY ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 185. GERMANY ANTI-TUMOR DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 186. GERMANY ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 187. GERMANY ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 188. ISRAEL ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
TABLE 189. ISRAEL ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 190. ISRAEL ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 191. ISRAEL ANTI-TUMOR DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 192. ISRAEL ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 193. ISRAEL ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 194. ITALY ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
TABLE 195. ITALY ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 196. ITALY ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 197. ITALY ANTI-TUMOR DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 198. ITALY ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 199. ITALY ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 200. NETHERLANDS ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
TABLE 201. NETHERLANDS ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 202. NETHERLANDS ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 203. NETHERLANDS ANTI-TUMOR DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 204. NETHERLANDS ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 205. NETHERLANDS ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 206. NIGERIA ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
TABLE 207. NIGERIA ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 208. NIGERIA ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 209. NIGERIA ANTI-TUMOR DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 210. NIGERIA ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 211. NIGERIA ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 212. NORWAY ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
TABLE 213. NORWAY ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 214. NORWAY ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 215. NORWAY ANTI-TUMOR DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 216. NORWAY ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 217. NORWAY ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 218. POLAND ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
TABLE 219. POLAND ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 220. POLAND ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 221. POLAND ANTI-TUMOR DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 222. POLAND ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 223. POLAND ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 224. QATAR ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
TABLE 225. QATAR ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 226. QATAR ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 227. QATAR ANTI-TUMOR DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 228. QATAR ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 229. QATAR ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 230. RUSSIA ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
TABLE 231. RUSSIA ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 232. RUSSIA ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 233. RUSSIA ANTI-TUMOR DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 234. RUSSIA ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 235. RUSSIA ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 236. SAUDI ARABIA ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
TABLE 237. SAUDI ARABIA ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 238. SAUDI ARABIA ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 239. SAUDI ARABIA ANTI-TUMOR DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 240. SAUDI ARABIA ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 241. SAUDI ARABIA ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 242. SOUTH AFRICA ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
TABLE 243. SOUTH AFRICA ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 244. SOUTH AFRICA ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 245. SOUTH AFRICA ANTI-TUMOR DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 246. SOUTH AFRICA ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 247. SOUTH AFRICA ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 248. SPAIN ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
TABLE 249. SPAIN ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 250. SPAIN ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 251. SPAIN ANTI-TUMOR DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 252. SPAIN ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 253. SPAIN ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 254. SWEDEN ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
TABLE 255. SWEDEN ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 256. SWEDEN ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 257. SWEDEN ANTI-TUMOR DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 258. SWEDEN ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 259. SWEDEN ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 260. SWITZERLAND ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
TABLE 261. SWITZERLAND ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 262. SWITZERLAND ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 263. SWITZERLAND ANTI-TUMOR DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 264. SWITZERLAND ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 265. SWITZERLAND ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 266. TURKEY ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
TABLE 267. TURKEY ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 268. TURKEY ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 269. TURKEY ANTI-TUMOR DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 270. TURKEY ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 271. TURKEY ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 272. UNITED ARAB EMIRATES ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
TABLE 273. UNITED ARAB EMIRATES ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 274. UNITED ARAB EMIRATES ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 275. UNITED ARAB EMIRATES ANTI-TUMOR DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 276. UNITED ARAB EMIRATES ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 277. UNITED ARAB EMIRATES ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 278. UNITED KINGDOM ANTI-TUMOR DRUGS MARKET SIZE, BY INDICATIONS, 2018-2030 (USD MILLION)
TABLE 279. UNITED KINGDOM ANTI-TUMOR DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 280. UNITED KINGDOM ANTI-TUMOR DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 281. UNITED KINGDOM ANTI-TUMOR DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 282. UNITED KINGDOM ANTI-TUMOR DRUGS MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 283. UNITED KINGDOM ANTI-TUMOR DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 284. ANTI-TUMOR DRUGS MARKET, FPNV POSITIONING MATRIX, 2022
TABLE 285. ANTI-TUMOR DRUGS MARKET SHARE, BY KEY PLAYER, 2022
TABLE 286. ANTI-TUMOR DRUGS MARKET LICENSE & PRICING

以下、関連資料のご紹介